Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder

– Company expects to initiate Phase 3 pivotal trial in late summer 2024 – – Phase 3 pivotal study to include 30 clinical sites across the United States and Europe with deep expertise in depression studies – – Pivotal tri